Caring Hands Patient Advocate

Now that a plethora of clinical trials have established positive responses from immunotherapies—immune checkpoint inhibitors, in particular—in patients with a variety of cancer types, one of the logical next questions is, are the responses durable?

Source: AACR Annual Meeting 2017: Immunotherapy Provides Long-lasting Responses to Certain Cancer Types – CANCER RESEARCH Catalyst